Michael F. Good
Good, Michael F.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Good, Michael Francis
VIAF ID: 42152561591415441833 (Personal)
Permalink: http://viaf.org/viaf/42152561591415441833
Preferred Forms
-
100 1 0
‡a
Good, Michael F.
-
100 1 _
‡a
Good, Michael F.
-
100 1 _ ‡a Good, Michael F.
-
100 1 _
‡a
Good, Michael Francis
-
100 0 _
‡a
Michael F. Good
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. |
|
| Mixed results for a malaria vaccine |
|
| Molecular immunological considerations in malaria vaccine development, 1993: |
|
| Nanovaccines and their mode of action. |
|
| Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1. |
|
| The need for assays predictive of protection in development of malaria bloodstage vaccines |
|
| Neonatal exposure to immunogenic peptides. Differential susceptibility to tolerance induction of helper T cells and B cells reactive to malarial circumsporozoite peptide epitopes. |
|
| A novel pathway of haematopoiesis revealed after experimental malaria infection |
|
| Novel platform technology for modular mucosal vaccine that protects against streptococcus. |
|
| PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. |
|
| Peptide immunization can elicit malaria protein-specific memory helper but not proliferative T cells. |
|
| Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys |
|
| Plasmodium berghei bio-burden correlates with parasite lactate dehydrogenase: application to murine Plasmodium diagnostics |
|
| Plasmodium falciparum-specific T cell clones from non-exposed and exposed donors are highly diverse in TCR beta chain V segment usage |
|
| Plasmodium strain determines dendritic cell function essential for survival from malaria |
|
| Plasmodium yoelii can ablate vaccine-induced long-term protection in mice |
|
| Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus |
|
| Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. |
|
| Polymorphism in the circumsporozoite (CS) protein of Plasmodium falciparum |
|
| Polyspecific malaria antibodies present at the time of infection inhibit the development of immunity to malaria but antibodies specific for the malaria merozoite surface protein, MSP1, facilitate immunity |
|
| Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. |
|
| Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate. |
|
| Profoundly Reduced CD1c+ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection |
|
| Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of nonexposed donors |
|
| Prospective surveillance of streptococcal sore throat in a tropical country |
|
| Protection of rats against malaria by a transplanted immune spleen |
|
| Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70 |
|
| Protein antigenic structures recognized by T cells: potential applications to vaccine design |
|
| The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria |
|
| The quest for GAS vaccine |
|
| The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation |
|
| Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. |
|
| The relevance of non-human primate and rodent malaria models for humans |
|
| Research toward malaria vaccines |
|
| Restricted or absent immune responses in human populations to plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies |
|
| Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice |
|
| A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria |
|
| Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes |
|
| The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus |
|
| The role of the 19-kDa region of merozoite surface protein 1 and whole-parasite-specific maternal antibodies in directing neonatal pups' responses to rodent malaria infection |
|
| Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine |
|
| Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge |
|
| Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines |
|
| Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy. |
|
| Soluble CD38 significantly prolongs the lifespan of memory B-cell responses. |
|
| Status of research and development of vaccines for Streptococcus pyogenes |
|
| Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci |
|
| Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma. |
|
| Summary of the meeting on cellular mechanisms in malaria immunity |
|
| Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. |
|
| Synthesis, Characterization and Immunological Evaluation of Self-Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties. |
|
| A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia |
|
| Synthetic peptides from P.falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: The role of IL-2 and conformational structure on immunogenicity of Pfs25 |
|
| Systemic tumor necrosis factor generated during lethal Plasmodium infections impairs dendritic cell function |
|
| T-cell antigenic sites of the malaria circumsporozoite protein. |
|
| T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: relevance to vaccine development |
|
| T cells, T sites, and malaria immunity--further optimism for vaccine development |
|
| Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage |
|
| Towards a blood-stage vaccine for malaria: are we following all the leads? |
|
| Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci |
|
| Towards the development of the ideal malaria vaccine. A decade of progress in a difficult field. |
|
| Vaccination against rheumatic heart disease: a review of current research strategies and challenges |
|
| Vaccine delivery: synthesis and investigation of a highly pure, multi-epitopic lipopeptide vaccine candidate. |
|
| Vaccine delivery utilizing liposaccharides |
|
| Vaccine-induced immunity to malaria parasites and the need for novel strategies |
|
| What have we learnt from mouse models for the study of malaria? |
|
| What really happens to dendritic cells during malaria? |
|
| Whole organism blood stage vaccines against malaria |
|
| Whole parasite vaccines for the asexual blood stages of Plasmodium |
|
